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Transcriptional activation by Tat protein is in large part dependent on interactions with the TAR RNA element located in the
59-untranslated region of all human immunodeficiency virus type 1 (HIV-1) transcripts. In addition, Tat has been shown to
induce nuclear translocation of nuclear factor-kB (NF-kB), potentially contributing to gene induction. The NF-kB responsive
reporter construct, (PRDII)4-CAT, was used to explore transcription resulting from NF-kB activated by Tat. Tat did not activate
(PRDII)4-CAT, whereas (PRDII)4-CAT was highly responsive to either transfected Rel A or to tumor necrosis factor-a (TNF-a).
Despite its inability to directly induce, Tat enhanced the responsiveness of (PRDII)4-CAT to either transfected Rel A or to
TNF-a by ;2.5-fold. High levels of CAT activity were seen with HIV-LTR-derived reporters that contained kB and TAR
elements in response to transfected Tat in the absence of either transfected Rel A or exogenous TNF-a, and overexpression
of IkBa with Tat inhibited CAT activity by 60% to 80%, suggesting that some activation of NF-kB by Tat was occurring. HIV-LTR
reporter activities were enhanced three fold to sixfold compared with Tat alone when additional NF-kB was provided by
transfection or by activation with TNF-a. These data indicate that Tat is unable to activate some NF-kB-responsive promoters
but is able to synergize with NF-kB in the activation of both HIV-derived and non-HIV-derived promoters. © 1999 Academic Press
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fINTRODUCTION
Tat regulates human immunodeficiency virus type 1
HIV-1) gene expression through a mechanism involving
oth viral and cellular components. Transactivation of
IV-1 gene expression is in part dependent on the inter-
ction between Tat and TAR, an RNA stem-loop structure
resent at the 59 end of all viral transcripts (Berkhout et
l., 1990; Garcia et al., 1989). The binding of Tat to TAR is
acilitated by the interaction of Tat with P-TEFb, the hu-
an homolog of the multisubunit-positive transcription
longation factor of Drosophila (Peng et al., 1998; Zhu et
l., 1997). The cyclin T1 subunit of P-TEFb interacts di-
ectly with sequences within the activation domain of Tat
nd promotes the binding of Tat to TAR (Wei et al., 1998).
he partner to cyclin T1 and the catalytic component of
-TEFb is the cyclin-dependent kinase 9 (cdk9), whose
ctivity is crucial for Tat transactivation of the HIV-1
romoter (Mancebo et al., 1997; Zhu et al., 1997). P-TEFb
ncreases the phosphorylation level of the carboxyl-ter-
inal domain of the RNA polymerase II enzyme (Herr-
ann and Rice, 1995; Yang et al., 1996), converting the
nzyme into a processive form that is able to efficiently
longate transcription. The increased transcriptional pro-
1 To whom reprint requests should be addressed at Winship Cancer
enter, 1365-B Clifton Road NE. Fax: (404) 778-3965. E-mail: mofferm@cmory.edu.
042-6822/99 $30.00
opyright © 1999 by Academic Press
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128essivity and elongation are believed in large part to
ccount for the increased levels of HIV-1 transcripts seen
n response to Tat. The transcriptional effects of Tat,
owever, are also exerted at the level of transcription
nitiation. Tat has been shown to activate the transcrip-
ion factor nuclear factor-kB (NF-kB) (Conant et al., 1996;
emarchi et al., 1996; Kelly et al., 1998). Tat also interacts
ith and recruits to the HIV-1 promoter cellular proteins
ontaining histone acetyltransferase activity, such as
/CAF and the coactivator p300/CBP (Benkirane et al.,
998; Hottinger and Nabel, 1998; Marzio et al., 1998), that
id in remodeling the chromatin structure and alleviating
ts repressive effects on transcription of the integrated
IV-1 provirus (Benkirane et al., 1998; Marzio et al., 1998).
Optimal HIV-1 gene expression and responsiveness to
at require intact kB enhancer elements and TATA-box
equences in the HIV-1 promoter (Berkhout et al., 1990;
erkhout and Jeang, 1992; Garcia et al., 1989; Olsen and
osen, 1992), and deletion of kB and SP-1 sequences
rom the HIV-LTR dramatically attenuates Tat responsive-
ess (Berkhout et al., 1990). The IkB family members
kBa, IkBb, and NFKB2 inhibit Tat transactivation of a
ild-type HIV-1 reporter in a manner that correlates with
heir ability to inhibit the binding of the Rel A subunit of
F-kB to a palindromic kB probe in gel shift assays
Harhaj et al., 1996). Furthermore, transdominant mutant
orms of IkB have been shown to affect the HIV-1 life
ycle, leading to a block in virus multiplication in single-
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129TAT AND NF-kB INTERACTIONSycle infection models (Beauparlant et al., 1996). These
indings suggest that the function of Tat is in part depen-
ent on the nuclear translocation of NF-kB and that
ctivation of NF-kB occurs in response to Tat. Exogenous
at activates NF-kB in Kaposi’s sarcoma (KS) cells and
nduces the expression of multiple inflammatory re-
ponse genes that are in part regulated by NF-kB (Kelly
t al., 1998). Increased NF-kB activation in response to
table expression of Tat or addition of exogenous Tat has
lso been observed in astrocytes and Jurkat and HeLa
ells (Conant et al., 1996; Demarchi et al., 1996; Ramaz-
otti et al., 1996; Westendorp et al., 1995). The mecha-
ism by which Tat activates NF-kB is currently not
nown, but it is sensitive to antioxidants (Demarchi et al.,
996; Westendorp et al., 1995) and proteosome inhibitors
Conant et al., 1996; Demarchi et al., 1996), suggesting
hat the pathway by which Tat activates NF-kB shares
omponents with other studied NF-kB activation path-
ays.
Although activation of NF-kB occurs in response to
at, synergistic responses of the HIV-1 promoter to Tat
ccur when additional NF-kB is provided either through
ransfection or through activation by an exogenous fac-
or, such as tumor necrosis factor-a (TNF-a) (Beauparlant
t al., 1996; Liu et al., 1992). Tat and TNF-a lead to a
ynergistic increase in HIV-1 gene expression that is
ependent on NF-kB activation, and the increase is lost
n the presence of IkBa or mutants of Tat that no longer
an bind to the TAR element (Beauparlant et al., 1996).
hese data suggest that either the amount or form of
F-kB that is activated in response to Tat is insufficient
o achieve maximal induction of the HIV-1 promoter and
hat Tat transactivation is optimized by providing addi-
ional NF-kB.
Some responses to Tat do not occur at the nuclear
evel but result from an interaction between Tat and an
xtracellular structure or receptor. Because neither the
echanism involved in the activation of NF-kB by Tat nor
he mechanism involved in the functional interactions
etween Tat and NF-kB is known, these other activities
f Tat must be considered. Tat is an angiogenic factor,
eading cytokine-activated vascular endothelial cells to
orm capillary-like networks in culture and promoting
ew blood vessel formation in combination with basic
ibroblast growth factor (Albini et al., 1995). This angio-
enic effect is believed to result from Tat-mediated acti-
ation of the mitogen-activated protein (MAP) kinase
athway through an interaction with the vascular endo-
helial growth factor receptor Flk-1/KDR (Albini et al.,
996; Ganju et al., 1998). The basic domain of Tat (lo-
ated between amino acids 42–64) contains residues
hat are responsible for interacting with the Flk-1 recep-
or (Albini et al., 1996), thereby activating MAP kinase.
he basic domain region also mediates the interaction
etween Tat and CBP/p300 (Hottinger and Nabel, 1998),
hereas the RGD domain spanning amino acids 65–80 ff Tat interacts with integrins on the surface of cells
romoting the proliferation KS cells and cytokine-acti-
ated endothelial cells (Barillari et al., 1993; Brake et al.,
990; Vogel et al., 1993).
Studies reporting the activation of NF-kB by Tat have
ot determined the mechanism responsible for the acti-
ation or whether Tat-activated NF-kB is functionally
quivalent to NF-kB activated by other mechanisms,
uch as TNF-a. In addition, the ability of Tat and NF-kB to
ynergize in the context of promoters other than that of
IV-1 has not been examined. We therefore examined
he ability of endogenously expressed wild-type or mu-
ant forms of Tat to induce NF-kB-responsive reporters
nd to interact with NF-kB provided via either transfec-
ion or incubation with TNF-a. We demonstrate that Tat
s unable to activate the NF-kB-responsive reporter
PRDII)4-CAT, yet overexpression of IkBa dramatically
ttenuates the ability of Tat to induce Tat-responsive
eporters, suggesting that some activation of NF-kB by
at is occurring and contributing to Tat responsiveness.
e also demonstrate that Tat and NF-kB synergistically
nhance the expression of both NF-kB and Tat-respon-
ive reporters. Domains of Tat and cis elements of the
IV-1 promoter that are important for responsiveness are
lso defined.
RESULTS
To examine the functional consequences of NF-kB
ctivation by Tat in the absence of TAR-mediated events,
n NF-kB-responsive reporter construct, (PRDII)4-CAT,
hat contains no characterized TAR-like element was
sed in transient transfection assays. The construct
PRDII)4-CAT contains the kB element from the IFNb
romoter repeated in quadruplicate upstream of the
hloramphenicol acetyltransferase (CAT) gene (Fig. 1A).
ransfection of an expression vector for wild-type Tat
Fig. 1B) did not increase the activity of (PRDII)4-CAT
bove that of basal levels (Figs. 2A and 2B), whereas
PRDII)4-CAT was responsive to activation by either a
ransfected Rel A expression plasmid (Fig. 2A) or by
ctivation of NF-kB by TNF-a (Fig. 2B). Activation of the
eporter by cotransfection of Rel A with p50 did not differ
rom the response to Rel A alone (data not shown).
lthough Tat alone did not increase (PRDII)4-CAT activity,
t enhanced the response of this reporter to Rel A or to
NF-a (Figs. 2A and 2B). The mean enhancement that
ccurred in response to Tat combined with either trans-
ected Rel A or exogenous TNF-a ranged from 1.6- to
.4-fold when examined in six separate experiments
data not shown). Higher concentrations of transfected
at did not alter this response (data not shown). Because
at enhanced responsiveness to NF-kB activated by
NF-a as well as to transfected Rel A, the response to
at was not merely due to an enhancement of expressionrom the Rel A expression vector. To determine which
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130 KELLY, MORRIS, AND OFFERMANNomains of Tat may be necessary for the observed en-
ancement, expression vectors encoding various mu-
ants of Tat (Fig. 1B) were used in transient expression
ssays. The mutant D2-36 containing a deletion of amino
cids 2–36 within the N-terminal transactivation domain
f Tat (Rice and Carlotti, 1990b) was unable to enhance
ctivation of (PRDII)4-CAT in response to Rel A (Fig. 2A).
utants containing single amino acid substitutions
ithin critical residues of the transactivation domain of
at were used to refine the analysis. The mutants Cys22
nd Cys30 contain single amino acid substitutions of a
ysteine residue for glycine, have intact TAR-binding
otifs, and are unable to transactivate HIV-1 gene ex-
ression (Rice and Carlotti, 1990a). These two point mu-
ants were also unable to enhance responsiveness to
el A (Fig. 2A) or to TNF-a (Fig. 2B). This indicates that
he transactivation domain of Tat contains critical resi-
FIG. 1. Schematic representation of plasmid constructs. (A) The vario
B elements from the interferon-b promoter linked to the CAT gene
ownstream of 2453 linked to the CAT reporter gene (Okamoto and Wo
s its only HIV-1 sequences linked to the CAT gene (Kunsch et al., 199
hat the kB elements have been mutated so as to no longer be able to
long with various mutant forms. The mutants contain deletions or poin
ectors contain cDNA for each version of Tat driven by the cytomegalues that are necessary for Tat to enhance (PRDII)4-CAT activation by NF-kB. The mutant D57 that contains a
eletion of amino acids after residue 57 retained wild-
ype activity with respect to enhancing responsiveness
o NF-kB. This mutant contains an intact transactivation
omain and residues within the basic domain that are
ritical for binding TAR but lacks the RGD domain that is
mportant for mediating specific extracellular effects that
at exerts on certain cell types. To determine whether the
at-mediated enhancement was restricted to NF-kB,
ransfections were performed with the reporter (PRDI)4-
AT. This reporter contains four interferon regulatory
actor 1 (IRF-1) response elements in the same vector
ackbone as (PRDII)4-CAT. Transfected Tat did not in-
rease the activity of (PRDI)4-CAT above basal levels but
id cause a 1.7-fold enhancement of IRF-1-mediated re-
orter activity (data not shown). This increase was sim-
lar to the increase that occurred in response to NF-kB
rter plasmids used in this study are shown. (PRDII)4-CAT contains four
nd Maniatis, 1989). pCD12 contains wild-type HIV-1 LTR sequences
al, 1986). p(HIVkB)4-CAT contains four HIV-kB sites and a TAR element
HIVkB)4-CAT contains the same sequences as p(HIVkB)4-CAT, except
F-kB. (B) The expression vector for the wild-type Tat protein is shown
ions that substitute a glycine for a cysteine residue. These expression
mmediate-early promoter.us repo
(Fan a
ng-Sta
2). p(m
bind N
t mutatnd Tat, indicating that Tat-mediated enhancement could
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131TAT AND NF-kB INTERACTIONSccur with other transcription factor and enhancer ele-
ent pairs.
To examine the responsiveness to Tat and NF-kB of a
romoter containing kB and TAR elements, a reporter,
CD12, containing the wild-type, full-length HIV-1 pro-
oter linked to the CAT gene was used in cotransfection
xperiments (Fig. 1A). Transfected wild-type Tat, as ex-
ected, was able to strongly drive expression (1280-fold
ncrease) from this reporter (Fig. 3A). In contrast, neither
ransfected Rel A (Fig. 3A) nor TNF-a (data not shown)
etectably activated pCD12 despite the presence of sev-
ral kB elements in the HIV-1 promoter. The combination
f Tat and Rel A, however, led to a synergistic increase in
CD12 reporter activity (Figs. 3A and 3B). Differences in
bsolute cpm/b-galactosidase (b-gal) seen in the sepa-
ate experiments shown in Figs. 3A and 3B were due to
FIG. 1ifferent amounts of cellular extracts used for the deter- sination of CAT and b-gal activity. The synergy ranged
rom threefold to sevenfold in response to Rel A and Tat
ompared with Tat alone in replicate experiments. The
ransactivation domain mutants of Tat failed to transac-
ivate pCD12 by themselves and were unable to syner-
ize with Rel A. The mutant D57 had less ability than
ild-type Tat to induce expression of pCD12 but retained
aximal ability to synergize with Rel A. These data indi-
ate that the transactivation domain of Tat is necessary
or synergy with NF-kB in the activation of the HIV-1
romoter found in pCD12.
To determine whether NF-kB activation was critical for
esponsiveness of pCD12 to Tat, an expression vector for
kBa was used in transfection assays to inhibit NF-kB
ctivation. The presence of IkBa lowered but did not
liminate the response of pCD12 to Tat alone (Fig. 3B),
inueduggesting, as has been observed by others (Biswas et
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132 KELLY, MORRIS, AND OFFERMANNl., 1995), that some, but not all, of the ability of Tat to
ransactivate the HIV-1 promoter was dependent on the
resence of activated NF-kB. As expected, coexpression
f IkBa with Tat and Rel A reduced pCD12 activity to the
evel that occurred in response to Tat and IkBa, indicat-
ng that IkBa fully blocked responsiveness to transfected
el A.
Although pCD12 was unresponsive to NF-kB in the
bsence of Tat, the reporter p(HIVkB)4-CAT was compa-
ably responsive to either Tat or to NF-kB regardless of
hether NF-kB was provided through transfection of Rel
or through activation with TNF-a (Figs. 4A and 4B). This
eporter contains duplication of the tandem HIV-kB sites
nd retains the TAR element but lacks SP1 sites and
pstream elements of the HIV-LTR (Fig. 1A). In addition,
FIG. 2. Effect of Tat alone or in combination with NF-kB on (PRD
PRDII)4-CAT alone or in combination with 0.1 mg of pCMV-p65 (Rel A) a
B) HeLa cells were transfected with (PRDII)4-CAT with and without Ta
dded to cells 30 h posttransfection, and incubation was continued fo
EF-lacZ was used in each transfection condition. Cells were harves
enoted on the y-axis are cpm standardized to the relative b-gal for
erformed in triplicate 6 standard deviation.(HIVkB)4-CAT displayed a synergistic response to the tresence of Tat and NF-kB. The mutant D2-36 as well as
he mutants Cys22 and Cys30 were unable to transacti-
ate p(HIVkB)4-CAT or synergize with NF-kB (Figs. 4A
nd 4B), indicating that the transactivation domain is
ecessary for the ability of Tat to transactivate and syn-
rgize with Rel A in the expression of p(HIVkB)4-CAT. D57
as as effective as wild-type Tat in driving the expres-
ion of p(HIVkB)4-CAT. This contrasts to the impaired
bility D57 exhibited in transactivating pCD12. D57 was
s effective as wild-type Tat in synergizing with NF-kB
ith p(HIVkB)4-CAT, and this is similar to the synergy that
ccurred with D57 and NF-kB in the synergistic activa-
ion of pCD12. Taken together, these experiments indi-
ate that the sequences of Tat that are necessary for
ransactivation and for synergy with NF-kB reside within
T reporter activity. (A) HeLa cells were transfected with 0.25 mg of
.1 mg of the expression vectors for wild-type and mutant forms of Tat.
sion vectors as in part A. TNF-a, at a concentration of 10 ng/ml, was
before harvesting. As a control for transfectional efficiency, 0.5 mg of
h posttransfection and assayed for b-gal and CAT activities. Values
ample. The results depicted in each figure are from one experimentII)4-CA
nd/or 0
t expres
r 18 h
ted 48
each she transactivation domain of Tat, whereas sequences
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133TAT AND NF-kB INTERACTIONSfter residue 57, including the RGD domain, are not
ecessary for synergy with NF-kB.
A reporter construct derived from p(HIVkB)4-CAT that
ontained mutated kB elements that were no longer
apable of binding NF-kB was used to determine the
ontribution of the kB elements to Tat and NF-kB respon-
iveness. This reporter, p(mHIVkB)4-CAT, was still re-
ponsive to Tat, as seen in Fig. 4C, albeit the response
as much lower in magnitude. p(mHIVkB)4-CAT was not
esponsive to Rel A, and the combination of Rel A and Tat
id not increase the level of activation above that seen
FIG. 3. Effect of Tat alone and in combination with NF-kB and/or IkB
he reporter pCD12 alone or in combination with 0.1 mg of pCMV-p65 (R
eLa cells were transfected with 0.25 mg of the reporter pCD12 alone
mg of pCMV-IkBa. The stimulation with TNF-a was performed as
oncentration of 0.5 mg in each transfection condition. Cells were harv
enoted on the y-axis are cpm values standardized to the relative b-ga
erformed in triplicate 6 standard deviation.ith Tat alone. Thus the presence of intact kB elements as necessary for optimal Tat transactivation and synergy
ith NF-kB.
The effect of eliminating NF-kB on Tat transactivation
nd synergistic activation of p(HIVkB)4-CAT was also
xamined by transient expression of IkBa. At the con-
entrations tested, the IkBa plasmid reduced but did not
bolish the high levels of p(HIVkB)4-CAT activity seen
ith Tat alone (Fig. 5A). The same concentrations of the
kBa plasmid completely inhibited the response of this
eporter to Rel A. The ability of IkBa to partly, yet not
otally, inhibit the response of p(HIVkB)4-CAT to Tat trans-
D12 reporter activity. (A) HeLa cells were transfected with 0.25 mg of
nd/or 0.1 mg of the expression vectors for wild-type and mutant Tat. (B)
ombination with 0.5 mg of pCMV-p65 (Rel A), 0.1 mg of pCMV-Tat, and
for the experiment in Fig. 2B. The plasmid pEF-lacZ was used at a
8 h posttransfection and assayed for b-gal and CAT activities. Values
y for each sample. The results in each figure are from one experimenta on pC
el A) a
or in c
stated
ested 4
l activitctivation suggests that Tat activates p(HIVkB)4-CAT in
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135TAT AND NF-kB INTERACTIONSart through the activation of NF-kB and through a mech-
nism that is not dependent on the presence of NF-kB.
he synergistic response of this reporter to Tat and Rel A
n the presence of IkBa was lost, with levels being
omparable to that seen with Tat and IkB alone (Fig. 5B).
his result demonstrates the effectiveness of IkBa in
locking responses to NF-kB, including the synergy re-
ulting from NF-kB and Tat.
DISCUSSION
Although Tat has been reported to activate NF-kB in a
ariety of cell types (Demarchi et al., 1996; Kelly et al.,
998; Ramazzotti et al., 1996; Westendorp et al., 1995),
ur experiments demonstrate that not all kB-responsive
romoters are transactivated by Tat. (PRDII)4-CAT is
ighly inducible by either transfected Rel A or by the
F-kB that results from incubation with TNF-a, but it is
ompletely unresponsive to transfected Tat. Tat is clearly
xpressed in the situations in which it does not induce
PRDII)4-CAT activity because it leads to high levels of
ctivation of pCD12 and p(HIVkB)4-CAT when transfected
nder identical conditions. Furthermore, Tat enhances
esponsiveness of (PRDII)4-CAT to NF-kB even though it
s unable to directly induce (PRDII)4-CAT. Although this
ight suggest that transfected Tat does not activate
F-kB, responsiveness of both p(HIV-kB)4-CAT and
CD12 to Tat is dramatically reduced by coexpression of
kBa, suggesting that some NF-kB is activated by Tat,
hereby contributing to these promoter activities. In-
reased activation of NF-kB as assessed by DNA bind-
ng has been reported to occur in HeLa cells that either
tably express Tat or have been incubated with exoge-
ous Tat (Demarchi et al., 1996; Westendorp et al., 1995),
ut the functional consequences of the increased NF-kB
ere not reported. NF-kB is a dimer, and functionally
istinct activities can arise through different combina-
ions of Rel family members with different transactivation
apabilities and DNA-binding specificities (Baeuerle and
enkel, 1994; Ghosh et al., 1998; Kunsch, et al., 1992).
he lack of response of (PRDII)4-CAT to Tat might there-
ore be a result of insufficient levels of NF-kB activation
r activation of an NF-kB species that is distinct from that
ctivated by TNF-a that is not capable of driving expres-
ion from the kB elements in (PRDII)4-CAT.
Although both pCD12 and p(HIVkB)4-CAT are derived
rom the HIV-LTR and are both strongly induced by Tat,
hey demonstrate dramatic differences in their respon-
FIG. 4. Effect of Tat alone and in combination with NF-kB on p(HIVk
eporter p(HIVkB)4-CAT alone or in combination with 0.1 mg of pCMV-p6
B) HeLa cells were transfected with p(HIVkB)4-CAT and Tat expression
0 h posttransfection, and incubation was continued for 18 h before ha
s the reporter. The plasmid pEF-lacZ was used at a concentration of 0.5
nd assayed for b-gal and CAT activities. Values denoted on the y-axi
he results in each figure are from one experiment performed in triplicate 6iveness to NF-kB. Despite the presence of tandem kB
ites in pCD12, negligible responsiveness is seen to
F-kB in the absence of Tat, whereas p(HIVkB)4-CAT is
nduced to as high of levels by NF-kB as by Tat. These
eporters differ in the duplication of kB elements in
(HIVkB)4-CAT and by deletion of SP1 sites and up-
tream sequences in p(HIVkB)4-CAT. pCD12 and
(HIVkB)4-CAT also differ in their responsiveness to the
57 mutant of Tat. Deletion of amino acids C-terminal to
mino acid 57 decreases the ability of Tat to transacti-
ate pCD12 but does not decrease transactivation of
(HIVkB)4-CAT compared with wild-type Tat. Despite the
eduction compared with wild-type Tat, high levels of
AT activity result when pCD12 is incubated with the D57
utant of Tat. Thus the deleted region is not essential; it
erely enhances reporter activity. The region that is
eleted in D57 contains an RGD domain that is known to
nteract with integrins and trigger intracellular signaling
vents (Barillari et al., 1993; Benelli et al., 1998; Brake et
l., 1990). It is possible that the higher activity resulting
rom wild-type Tat compared with D57 is a consequence
f such intracellular signals.
Despite differences in responsiveness to NF-kB and
57, both pCD12 and p(HIVkB)4-CAT show synergistic
nhancement of CAT activity in response to Tat and
F-kB. Furthermore, mutations that eliminate the trans-
ctivation function of Tat eliminate the synergy, whereas
ther mutations, including D57, do not diminish the mag-
itude of the synergy that occurs in response to Tat and
F-kB. The region of the Tat protein necessary for the
bserved synergy with NF-kB is identical to all the pro-
oter constructs examined. Tat mutants that contain a
eletion or amino acid substitutions within the transac-
ivation domain that render the protein incapable of
ransactivation of HIV-1 gene expression are unable to
ynergize with NF-kB. Sequences C-terminal to amino
cid residue 57 of Tat, however, are not necessary for
ynergy. We conclude that residues after amino acid 57,
ncluding the integrin binding RGD domain, are not re-
uired for synergy with NF-kB but do contribute to max-
mum induction in response to Tat that is seen with
CD12 but not with the other reporters examined.
Consistent with the ability of IkBa to fully inhibit the
ctivation of the p(HIVkB)4-CAT in response to Rel A but
ot to Tat, mutation of the kB sites in p(HIV-kB)4-CAT
educes, but does not eliminate, response to Tat but fully
locks the synergy resulting from Tat and NF-kB. Based
reporter activity. (A) HeLa cells were transfected with 0.25 mg of the
) and/or 0.1 mg of the expression vectors for wild-type and mutant Tat.
as in part A. TNF-a, at a concentration of 10 ng/ml, was added to cells
g. (C) HeLa cells were transfected as in part A using p(mHIVkB)4-CAT
ach transfection condition. Cells were harvested 48 h posttransfection
pm values standardized to the relative b-gal activity for each sample.B)4-CAT
5 (Rel A
vectors
rvestin
mg in e
s are c
standard deviation.
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136 KELLY, MORRIS, AND OFFERMANNn studies from other laboratories, mutation or deletion
f kB sites does not always prevent interactions between
at and NF-kB. This is illustrated by a study in which Tat
ombined with TNF-a was shown to activate an HIV-LTR
eporter construct that lacked kB sites even though nei-
her Tat nor TNF-a activated it individually (Beauparlant
t al., 1996). There appear to be circumstances during
FIG. 5. Inhibition of Tat responses by IkBa. (A) HeLa cells were
ransfected with 0.25 mg of the reporter p(HIVkB)4-CAT alone or in
ombination with 0.1 mg of pCMV-p65 (Rel A) or with 0.1 mg of pCMVTat
ith or without pCMV-IkBa in varying microgram amounts. (B) HeLa
ells were transfected as in part A except that the amount of pCMV-
kBa used was 1.0 mg. The plasmid pEF-lacZ was used at a concen-
ration of 0.5 mg in each transfection condition. Cells were harvested
8 h posttransfection and assayed for b-gal and CAT activities. Values
enoted on the y-axis are cpm values standardized to the relative b-gal
ctivity for each sample. The results in each figure are from one
xperiment performed in triplicate 6 standard deviation.hich synergy to Tat and NF-kB can occur in the ab- tence of kB sites, perhaps as a consequence of NF-kB
irectly binding to Tat that is bound to TAR.
Our experiments demonstrate that Tat does not
irectly transactivate the NF-kB-dependent reporter
PRDII)4-CAT, even though there is a major reduction in
he transcriptional response to Tat that occurs with
CD12 and p(HIVkB)4-CAT when IkBa is coexpressed.
his suggests that some activation of NF-kB occurs in
esponse to Tat, but it is incapable of driving (PRDII)4-
AT reporter activity. Our studies also illustrate that HIV-
TR-derived promoters that contain both kB and TAR
lements can differ dramatically in their responsiveness
o NF-kB yet still display synergistic responsiveness to
F-kB and Tat. The synergy that occurs in response to
at and NF-kB appears to be dependent on transactiva-
ion function of Tat and thus is not likely to result from
ome of the cell surface responses to Tat. These studies
llustrate the complexity of the relationship between Tat
nd NF-kB.
MATERIALS AND METHODS
ell culture and reagents
HeLa cells were obtained from American Type Culture
ollection (Rockville, MD). The cells were cultured in
ulbecco’s modified Eagle’s medium obtained from Cell-
ro (Herndon, VA) and maintained at 37°C and 5% CO2.
he medium was supplemented with 10% fetal calf se-
um, 2 mM L-glutamine, and 100 U/ml of penicillin–strep-
omycin mixture (GIBCO BRL Life Technologies, Inc.,
rand Island, NY). The cytokine TNF-a was obtained
rom Collaborative Biomedical Products (Bedford, MA).
lasmid constructs
The HIV-1 reporter plasmid pCD12 containing the U3
nd R regions of the HIV-1 LTR linked to the CAT gene
as been described previously (Okamoto and Wong-
taal, 1986). The (PRDII)4-CAT reporter contains four
B elements from the interferon-b promoter (Fan
nd Maniatis, 1989). The reporters p(HIVkB)4-CAT and
(mHIVkB)4-CAT, as well as the expression vector for Rel
, pCMV-p65, and IkBa, pCMV-IkB, were kindly provided
y Dr. Charles Kunsch and have been previously de-
cribed (Kunsch et al., 1992). Wild-type (pCMVTat) and
utant Tat (pCMVCys22, pCMVCys30, and pCMVD57)
xpression vectors were derived from plasmids contain-
ng Tat cDNA (from HXB2 proviral clone) inserted into the
GEM-1 vector that were generously provided by Dr.
ndrew P. Rice. Tat cDNA were subcloned into the pCMV
2S expression vector between the EcoRI and HindIII
ites, replacing E1A 12S sequences. The Tat mutant
2-36 was generated by cloning a Tat-specific PCR frag-
ent digested with KpnI and ApaI into the pcDNA3
InVitrogen, Carlsbad, CA) mammalian expression vec-
or. The plasmid pCMV12S.FS was described previously
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137TAT AND NF-kB INTERACTIONSnd was used as a negative control vector (Morris and
athews, 1991). The b-gal reporter pEF-lacZ contains
he lacZ gene downstream from the promoter of the
ukaryotic elongation factor-1 a promoter and was used
s a control for transfectional efficiency.
ransfections and reporter assays
All transfection conditions were performed in triplicate
or the calculation of standard deviation. The day before
ransfection, HeLa cells were equally split into 6-well
lates. HeLa cells were transfected using the FuGENE 6
ransfection reagent (Boehringer Mannheim, Indianapo-
is, IN) according to the manufacturer’s instructions.
riefly, 6 ml of the FuGENE 6 transfection reagent was
iluted in serum-free Dulbecco’s modified Eagle’s me-
ium in a volume of 100 ml for each transfection condi-
ion. This mixture was incubated for 5 min at room tem-
erature. DNA containing reporter constructs and ex-
ression vectors (DNA concentration adjusted to 2 mg
otal with pCMV12S.FS) was then added to this mixture
nd incubated for 15 min at room temperature. After this
ncubation, the DNA transfection mixture was added to
he cells. After 48 h, the cells were rinsed with PBS and
ncubated in 13 Reporter Lysis Buffer (Promega, Madi-
on, WI) for 15 min at room temperature. The cells were
hen scraped and underwent one cycle of rapid freeze/
hawing. A cell lysate was obtained by centrifugation at
4,000 rpm for 5 min at 4°C. b-Galactosidase assays
ere performed by incubating 100 ml of lysate with 100 ml
f b-gal assay buffer (100 mM sodium phosphate buffer,
H 7.3, 2 mM MgCl2, 100 mM b-mercaptoethanol, and
.33 mg/ml o-nitrophenyl-b-D-galactopyranoside) at room
emperature. Colorimetric changes were measured at
05 nm on a BioRad model 450 ELISA reader (Richmond,
A). Cell lysates assayed for CAT were heated at 60°C
or 10 min to inactivate endogenous deacetylases. The
ysates were diluted to allow measurements of CAT ac-
ivity within the linear range of the assay. These diluted
ell lysates were assayed for CAT activity by measuring
he amount of n-butyryl CoA (Pharmacia, Biotech, Gaith-
rsburg, MD) transferred to [14C]chloramphenicol as de-
cribed elsewhere (Kingston and Sheen, 1997). The re-
ults of the CAT assays were measured in an LKB Wallac
odel Rackbeta 1209 liquid scintillation counter. These
pm values were corrected by the relative b-gal value for
ach sample within each experiment and are given as
pm/b-gal.
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